Nutriband Inc.
09/12/2025 | Press release | Distributed by Public on 09/12/2025 09:50
Nutriband Publishes Q2 Report and Announces Key FDA Meeting for AVERSA™ Fentanyl
Nutriband Inc. has released its Q2 2026 financial and operational update, highlighting meaningful revenue growth and major progress in the development of AVERSA™ Fentanyl - the company's lead abuse-deterrent transdermal patch.
-
Contract manufacturing revenue rose 50% YoY, driven by the expansion of kinesiology tape production through Pocono Pharma.
-
The company reported $0.6M in revenue and closed the quarter with $6.9M in cash.
-
A critical FDA Type C meeting is scheduled for September 18, 2025, to discuss the upcoming Phase 1 clinical trial for AVERSA™ Fentanyl.
This innovative patch combines a proven opioid with Nutriband's proprietary abuse-deterrent technology and requires only a single Phase 1 study to demonstrate lower abuse potential.
The company plans to expand the AVERSA platform to Buprenorphine, a key therapy for opioid dependence.
Analysts maintain an Outperform rating with a $15 target price, citing the strong strategic focus and growth in contract revenues to support clinical advancement.
Nutriband Inc. published this content on September 12, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 12, 2025 at 15:50 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]